Description
SL-28 is an experimental compound currently in early-phase clinical development for advanced solid tumors, including colorectal cancer. Based on available trial data, this agent is being evaluated in a tumor-agnostic approach, suggesting it may target a molecular pathway common across multiple cancer types. The compound appears to be in Phase 1 dose-escalation studies to establish safety and preliminary efficacy signals.
Mechanism of Action
The specific molecular mechanism of action for SL-28 has not been publicly disclosed in available clinical trial documentation. Given its tumor-agnostic application, it likely targets a fundamental cellular process or oncogenic pathway present across multiple solid tumor types.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.